Home › Companies › 10X GENOMICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and 10X GENOMICS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2025: 4 items on 10X GENOMICS INC.’s Form 8-K, filed June 5, 2025: 2 approved · 2 passed (calculated).
Notable dissent: 1 director (14.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore 10X GENOMICS INC. in the interactive database Compare manager voting policies
These tallies are 10X GENOMICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Sri Kosaraju | 189,313,724 | 7,243,542 | 172,526 | -- | 19,837,766 | 96% | Passed (calculated) | — |
| Elect Director: Shehnaaz Suliman | 168,973,468 | 27,595,026 | 161,298 | -- | 19,837,766 | 86% | Passed (calculated) | — |
| 2. Ratification of Independent Registered Public Accounting Firm | 215,766,816 | 312,396 | 488,346 | -- | -- | 99.9% | Approved | — |
| 3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers | 164,321,765 | 32,192,042 | 215,985 | -- | 19,837,766 | 84% | Approved | — |
Source: 10X GENOMICS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.
See voting trends for Industrials companies, 2024-2025: shareholder support by sector and by company size.
282 asset managers disclosed a vote on at least one 10X GENOMICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Shehnaaz Suliman
10X GENOMICS INC.’s own tally for this item (“Elect Director: Shehnaaz Suliman”): 168,973,468 for, 27,595,026 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 37,993,917 for, 3,482,903 against, 5,725 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,468,494 | 1,745,533 | 0 | 0 | Mixed |
| ARK ETF Trust | 11,685,143 | 0 | 0 | 0 | For |
| Vanguard | 11,146,941 | 921 | 0 | 0 | For |
| BlackRock | 2,235,570 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 652,941 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 256,431 | 0 | 0 | 0 | For |
| TIAA | 0 | 193,983 | 0 | 0 | Against |
| Columbia Threadneedle | 128,546 | 0 | 0 | 0 | For |
| Global X | 0 | 123,044 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 0 | 120,562 | 0 | 0 | Against |
| ARK Venture Fund | 96,720 | 0 | 0 | 0 | For |
| Voya | 0 | 95,424 | 0 | 0 | Against |
| Morgan Stanley | 82,018 | 0 | 0 | 0 | For |
| Equitable | 55,370 | 26,354 | 0 | 0 | Mixed |
| Pacific Life | 81,614 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST III | 78,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 77,014 | 0 | 0 | 0 | For |
| Lincoln Financial | 3,416 | 63,860 | 0 | 0 | Mixed |
| Nationwide | 0 | 55,973 | 0 | 0 | Against |
| SEI | 0 | 50,514 | 0 | 0 | Against |
| Invesco | 0 | 50,328 | 0 | 0 | Against |
| PACE SELECT ADVISORS TRUST | 0 | 46,308 | 0 | 0 | Against |
| T. Rowe Price | 46,201 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 38,365 | 0 | 0 | Against |
Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve a three-year term expiring at the 2028 annual meeting of stockholders or until such director's successors are duly elected and qualified or until such director's earlier death, resignation, disqualification or removal: Sri Kosaraju
10X GENOMICS INC.’s own tally for this item (“Elect Director: Sri Kosaraju”): 189,313,724 for, 7,243,542 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 41,311,794 for, 165,026 against, 5,725 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,214,027 | 0 | 0 | 0 | For |
| ARK ETF Trust | 11,685,143 | 0 | 0 | 0 | For |
| Vanguard | 11,146,942 | 920 | 0 | 0 | For |
| BlackRock | 2,235,570 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 652,941 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 256,431 | 0 | 0 | 0 | For |
| TIAA | 193,983 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 128,546 | 0 | 0 | 0 | For |
| Global X | 123,044 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 120,562 | 0 | 0 | 0 | For |
| ARK Venture Fund | 96,720 | 0 | 0 | 0 | For |
| Voya | 0 | 95,424 | 0 | 0 | Against |
| Morgan Stanley | 82,018 | 0 | 0 | 0 | For |
| Equitable | 55,370 | 26,354 | 0 | 0 | Mixed |
| Pacific Life | 81,614 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST III | 78,523 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 77,014 | 0 | 0 | 0 | For |
| Lincoln Financial | 64,105 | 3,171 | 0 | 0 | For |
| Nationwide | 55,973 | 0 | 0 | 0 | For |
| SEI | 50,514 | 0 | 0 | 0 | For |
| Invesco | 50,328 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 46,308 | 0 | 0 | 0 | For |
| T. Rowe Price | 46,201 | 0 | 0 | 0 | For |
| ALGER FUNDS | 38,365 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
84% Approved · of votes cast
Prior year: 83.2% for (June 11, 2024 meeting) ▲ 0.4 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
10X GENOMICS INC.’s own tally for this item (“3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 164,321,765 for, 32,192,042 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,160,391 | 53,636 | 0 | 0 | For |
| ARK ETF Trust | 11,685,143 | 0 | 0 | 0 | For |
| Vanguard | 11,146,941 | 921 | 0 | 0 | For |
| BlackRock | 158,880 | 2,076,690 | 0 | 0 | Mixed |
| Capital Group | 0 | 1,452,300 | 0 | 0 | Against |
| Charles Schwab | 0 | 652,941 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 256,431 | 0 | 0 | 0 | For |
| TIAA | 0 | 193,983 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 128,546 | 0 | 0 | Against |
| Global X | 0 | 123,044 | 0 | 0 | Against |
| Exchange Place Advisors Trust | 0 | 120,562 | 0 | 0 | Against |
| ARK Venture Fund | 96,720 | 0 | 0 | 0 | For |
| Voya | 0 | 95,424 | 0 | 0 | Against |
| Morgan Stanley | 0 | 82,018 | 0 | 0 | Against |
| Equitable | 0 | 81,724 | 0 | 0 | Against |
| Pacific Life | 75,770 | 5,844 | 0 | 0 | Mixed |
| NORTHERN LIGHTS FUND TRUST III | 0 | 78,523 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 15,828 | 61,186 | 0 | 0 | Mixed |
| Lincoln Financial | 0 | 67,276 | 0 | 0 | Against |
| Nationwide | 0 | 55,973 | 0 | 0 | Against |
| SEI | 0 | 50,514 | 0 | 0 | Against |
| Invesco | 0 | 50,328 | 0 | 0 | Against |
| PACE SELECT ADVISORS TRUST | 0 | 46,308 | 0 | 0 | Against |
| T. Rowe Price | 0 | 46,201 | 0 | 0 | Against |
| ALGER FUNDS | 0 | 38,365 | 0 | 0 | Against |
Fund voting reports, all 59 managers: 35,663,218 for, 5,813,602 against, 5,725 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,761,308 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 0 | 5,389,611 | 0 | 0 | Against |
| BlackRock | 525,594 | 2,134,291 | 0 | 0 | Mixed |
| Two Sigma | 0 | 2,159,053 | 0 | 0 | Against |
| UBS | 0 | 2,111,528 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,962,561 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 0 | 1,655,103 | 0 | 0 | Against |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,505,585 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,452,300 | 0 | 0 | Against |
| State Street | 1,401,972 | 47,580 | 0 | 0 | For |
| Camber Capital Management LP | 0 | 1,000,000 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 751,273 | 0 | 0 | Against |
| Charles Schwab | 0 | 653,315 | 0 | 0 | Against |
| AQR | 0 | 601,164 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 525,945 | 0 | 0 | Against |
| Sands Capital Alternatives, LLC | 0 | 481,770 | 0 | 0 | Against |
| BOSTON MANAGEMENT & RESEARCH | 0 | 467,079 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 439,403 | 0 | 0 | Against |
| STATE OF MICHIGAN RETIREMENT SYSTEM | 0 | 399,413 | 0 | 0 | Against |
| ARK Investment Management LLC | 356,669 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 325,693 | 0 | 0 | Against |
| Amundi | 0 | 320,340 | 0 | 0 | Against |
| Northern Trust | 278,556 | 10,852 | 0 | 0 | For |
| Vestmark Advisory Solutions, Inc. | 0 | 285,137 | 0 | 0 | Against |
| Morgan Stanley | 0 | 274,764 | 0 | 0 | Against |
Institutional-manager reports, all 240 managers: 17,675,215 for, 25,639,523 against, 84,291 abstained, 50,939 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 11, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and
10X GENOMICS INC.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 215,766,816 for, 312,396 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 41,397,442 for, 79,378 against, 5,725 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,214,027 | 0 | 0 | 0 | For |
| ARK ETF Trust | 11,685,143 | 0 | 0 | 0 | For |
| Vanguard | 11,147,862 | 0 | 0 | 0 | For |
| BlackRock | 2,235,570 | 0 | 0 | 0 | For |
| Capital Group | 1,452,300 | 0 | 0 | 0 | For |
| Charles Schwab | 652,941 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 256,431 | 0 | 0 | 0 | For |
| TIAA | 193,983 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 128,546 | 0 | 0 | 0 | For |
| Global X | 123,044 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 120,562 | 0 | 0 | 0 | For |
| ARK Venture Fund | 96,720 | 0 | 0 | 0 | For |
| Voya | 95,424 | 0 | 0 | 0 | For |
| Morgan Stanley | 82,018 | 0 | 0 | 0 | For |
| Equitable | 81,724 | 0 | 0 | 0 | For |
| Pacific Life | 81,614 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST III | 0 | 78,523 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 77,014 | 0 | 0 | 0 | For |
| Lincoln Financial | 67,276 | 0 | 0 | 0 | For |
| Nationwide | 55,973 | 0 | 0 | 0 | For |
| SEI | 50,514 | 0 | 0 | 0 | For |
| Invesco | 50,328 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 46,308 | 0 | 0 | 0 | For |
| T. Rowe Price | 46,201 | 0 | 0 | 0 | For |
| ALGER FUNDS | 38,365 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 122,291,837 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.99% |
| 2 | ARK ETF Trust | 9.56% |
| 3 | Vanguard | 9.12% |
| 4 | BlackRock | 1.83% |
| 5 | Capital Group | 1.19% |
| 6 | Charles Schwab | 0.53% |
| 7 | AMERICAN BEACON FUNDS | 0.21% |
| 8 | TIAA | 0.16% |
| 9 | Columbia Threadneedle | 0.11% |
| 10 | Global X | 0.10% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 8.80% |
| 2 | Nikko Asset Management Co., Ltd. | 4.41% |
| 3 | BlackRock | 2.18% |
| 4 | Two Sigma | 1.77% |
| 5 | UBS | 1.73% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.60% |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 1.35% |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.23% |
| 9 | Capital Group | 1.19% |
| 10 | State Street | 1.19% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| ARK Investment Management LLC | 11,887,396 | 9.72% | Schedule 13G, filed November 4, 2025 |
| Vanguard Group | 11,118,086 | 9.09% | Form 13F, quarter ended March 31, 2025 |
| FMR (Fidelity) | 9,893,139 | 8.09% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Portfolio Management | 6,981,683 | 5.71% | Schedule 13G, filed April 28, 2026 |
| BlackRock | 6,667,822 | 5.45% | Form 13F, quarter ended March 31, 2025 |
| Nikko Asset Management Americas, Inc. | 6,009,653 | 4.91% | Schedule 13G, filed August 13, 2025 |
| Sumitomo Mitsui Trust Group, Inc. | 5,381,219 | 4.40% | Schedule 13G, filed October 27, 2025 |
| Millennium Management | 5,377,492 | 4.40% | Form 13F, quarter ended March 31, 2025 |
| Amova Asset Management Americas, Inc. | 5,376,883 | 4.40% | Schedule 13G, filed November 13, 2025 |
| Morgan Stanley | 2,774,091 | 2.27% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 122,291,837 shares outstanding, as reported by 10X GENOMICS INC. on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At 10X GENOMICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 282 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,184 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — 10X GENOMICS INC.'s filing reports the proposal as approved, with 84% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 10X GENOMICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 10X GENOMICS INC.’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
10X GENOMICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “10X GENOMICS (TXG) 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/10x-genomics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.